Neutrisci International Inc. and Falcon Technologies, Inc. announced that they have entered into a Letter of Intent to create a sublingual CBD tablet. NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early second quarter of 2019.